New challenges in cancer care: cardiovascular disease and environmental factors

FHS
June 21, 2024
10:12 am

Preclinical and epidemiologic evidence linking air pollution to cardio-oncology.

Heart Transplant Rejection drugs in development, 2023

GlobalData tracks 8 drugs in development for Heart Transplant Rejection by seven companies/universities/institutes. The top development phase for Heart Transplant Rejection is preclinical, with five

December 1, 2023

Actuate’s pancreatic cancer therapy gains EMA OMPD

Elraglusib is aimed at treating pancreatic ductal adenocarcinoma. Credit: Jo Panuwat D/Shutterstock. Actuate Therapeutics has gained orphan medicinal product designation (OMPD) from the European Medicines

January 8, 2025

The decline and fall of elite multispecialty medical groups

The failure of Geisinger Health System, which lost $842 million in 2022 and disappeared into a new Kaiser subsidiary called Risant, sent shockwaves through the

January 17, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.